

## SUPPLEMENTARY SECTION

### **Plasma cell but not CD20-mediated B cell depletion protects from bleomycin-induced lung fibrosis**

Cecilia M Prêl<sup>1,2,\*</sup>, Tylah Miles<sup>1,\*</sup>, David R Pearce<sup>3</sup>, Robert J O'Donoghue<sup>4</sup>, Chris Grainge<sup>5,6</sup>, Lucy Barrett<sup>1</sup>, Kimberly Birnie<sup>1</sup>, Andrew D Lucas<sup>1</sup>, Svetlana Baltic<sup>1</sup>, Matthias Ernst<sup>7</sup>, Catherine Rinaldi<sup>8</sup>, Geoffrey J Laurent<sup>1,2</sup>, Darryl A Knight<sup>9</sup>, Mark Fear<sup>1,5</sup>, Gerard Hoyne<sup>1,9</sup>, Robin J McNulty<sup>3,#</sup> and Steven E Mutsaers<sup>1,2,#</sup>

<sup>1</sup>Institute for Respiratory Health, The University of Western Australia, Nedlands WA Australia;

<sup>2</sup>Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Nedlands WA Australia; <sup>3</sup>Centre for Inflammation and Tissue Repair, Division

of Medicine, University College London, London UK; <sup>4</sup>Department of Pharmacology and

Therapeutics, University of Melbourne, VIC Australia; <sup>5</sup>Centre for Healthy Lungs, Hunter Medical

Research Institute, University of Newcastle, Newcastle, NSW, Australia; <sup>6</sup>Dept of Respiratory and

Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia; <sup>7</sup>Olivia Newton John Cancer

Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, VIC Australia;

<sup>8</sup>Centre for Microscopy Characterisation and Analysis, The University of Western Australia,

Nedlands WA Australia; <sup>9</sup>Providence Health Care Research Institute, Vancouver, BC, Canada; <sup>10</sup>Burn

Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Nedlands

WA Australia; <sup>11</sup>The University of Notre Dame Australia, Fremantle WA Australia.

## **Supplementary Methods**

### **Mouse lung and spleen dissociation and B cell phenotype analysis using flow cytometry.**

Mouse lung tissue was harvested and dissected into 1-2 mm<sup>3</sup> pieces and incubated in 3 mL digestion medium consisting of 48 µg/mL Liberase™ (Roche), 0.1 mg/mL of DNase I in RPMI (Gibco® Life Technologies™) for 2 h at 37°C with constant shaking. The enzymatic activity within the digestion medium was neutralised with 4 mL RPMI/10% FCS and the lung cells collected by centrifuging at 300 g for 5 min.

Spleen cells were isolated by teasing the spleen with two needles and then washed in PBS, pH7.4. The isolated cells were resuspended in hypotonic cell lysis buffer (150 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM Na<sub>2</sub>EDTA, pH 7.4), incubated at room temperature (RT) for 7 min and then topped up with PBS to lyse the red blood cells. PBMC were isolated on a lymphoprep gradient using Cell SepMate Tubes (Stem Cell Technologies, UK) in accordance with the manufacturer's guidelines. All cells were resuspended and frozen in cyro-preservation medium (RPMI 50% FCS/10% DMSO).

Flow cytometry antibodies were diluted in a solution of 50% PBS and 50% BD Horizon Brilliant Stain™ (BD Biosciences, Franklin Lake, NJ, USA). Mouse PBMCs, lung and spleen cells were stained in 50 µL of the B cell antibody cocktail (Supplementary Table S1) for 30 min on ice, washed twice in 100 µL of PBS/2% FCS and centrifuged at 300 g for 5 min. The cells were then resuspended in 200 µL of PBS/10% FCS and fixed with BD Cytfix/Cytoperm™ kit and stored at 4°C for up to 48 h. Flow cytometry was performed on BD LSRFortessa™ and analysis performed using FlowJo 10.3. B cell subsets were identified by flow cytometry; mature follicular B cells (CD45.2<sup>+</sup>CD19<sup>+</sup>CD20<sup>+</sup>), B1 regulatory B cells (CD45.2<sup>+</sup>CD19<sup>+</sup>CD20<sup>-</sup>CD38<sup>+</sup>CD5<sup>+</sup>CD43<sup>+</sup>) and

plasma cells (CD45.2<sup>+</sup>CD19<sup>+</sup>CD20<sup>-</sup>CD138<sup>+</sup>CD43<sup>+</sup>CD38<sup>+</sup>CD27<sup>+</sup>) or plasmablasts (CD45.2<sup>+</sup>CD19<sup>+</sup>CD20<sup>+</sup>CD138<sup>-</sup>CD43<sup>+</sup>CD38<sup>+</sup>CD27<sup>+</sup>).

**Histochemical and immunohistochemical analysis of fibrosis and immune cell infiltration in tissue.** Mouse and human lung sections (3 µm) were dewaxed, and antigen retrieval performed in a pressure cooker by boiling slides in citrate buffer for 10 minutes and cooling. Endogenous peroxidase and non-specific antibody binding blocking steps were performed and then the tissues were incubated with primary antibody or appropriate control mouse or rabbit IgG overnight at 4°C. Tissue sections were washed three times in TRIS Buffered Saline (TBS) and then incubated in the appropriate biotinylated secondary antibody for 45 min followed by streptavidin/HRP for 30 min at RT. Immunolabelling was visualised by incubating tissue sections in 3,3'-Diaminobenzidine solution (DAB) (Sigma-Aldrich®) for up to 5 min. For CD138 staining of mouse lung tissue the Vector® M.O.M™ Immunodetection kit was used according to the manufacturer's instructions. For the detection of CD19 and CD138 by immunofluorescence the sections were incubated in the appropriate AF568- and AF488-conjugated secondary antibodies for 30 min at RT. The nuclei were visualised by incubating the section in 4',6-diamidino-2-phenylindole (DAPI) for 5 min at RT. Representative tissue sections were also stained for hematoxylin and eosin, Masson's trichrome or Martius scarlet blue (MSB) trichrome staining using a Tissue-Tek DRA autostainer (Sakura, Japan). Slides were imaged using either the Aperio ScanScope® XT (Leica Biosystems, Centre for Microscopy, Characterisation and Analysis, UWA) or Nanozoomer HT slide scanner (Hamamatsu, Japan; University College London).